Boehringer Ingelheim Innovation Prize

2019年01月24日(木) 14時00分開始(受付13時30分) LINK-J 日本橋ライフサイエンスビルディング (https://www.link-j.org/access/)

14:00	Opening	
14:05	 "From Idea to Start-up" Henri Doods (BI): Translating Japanese research excellence into new medicines for patients Ioannis Sapountzis (BI): Boehringer Ingelheim's partnering strategy 	
14:50	Poster Presentation , Networking and Voting (1.5h)	
16:20	Guest Speakers 6:20 Christian Tidona (BioMed X - Germany): How to become a biotech entrepreneur Jean-Jacques Yarmoff (Biolabs - USA): Entrepreneur ecosystem in the USA (tbc)	
17:30	Pitch Presentation 5 Best	
18:00 Networking Dinner with German food and Prize Announcement		
20:00	End of the Meeting	協 賛: LINK- J
The development of antibody-drug conjugate (ADC) that targets sarcoma including osteosarcoma		Nobutoshi Esaki Nagoya University
Development of PTPRZ inhibitors as newly generated first-in-class compounds for cancer		Akihiro Fujikawa National Institute for Basic Biology
Tumor-Associated Macrophage-Targeted Antigen Delivery for the Treatment of Immune Resistant 'Cold' Tumors		Naozumi Harada United Immunity, Co., Ltd
Oligonucleotide therapeutics targeting extracellular miR-21 alleviate joint pain in osteoarthritis		Naoya Hoshikawa Nippon Medical School
Strategic development of molecularly-targeted anti-cancer agents using proteasome degradation system		Susumu Ito Showa Pharm. University
Development of in vivo gene therapy for Tay-Sachs disease by utilizing AAV9/3-modHEXB vector		Koji Itoh Tokushima University
Visual restoration gene therapy for retinitis pigmentosa		Yusaku Katada Restore Vision Co., Ltd
Kyoto University Substance, KUS121 – VCP ATPase inhibitor for central retinal artery occlusion		Kunihiro Musashi Kyoto Drug Discovery & Dev. Co., Ltd
Application of stealth RNA vector SRV to cancer gene cell therapy		Mahito Nakanishi TOKIWA-Bio Inc.
VNUT inhibitor as potential target for the treatment of NASH		Masatoshi Nomura Kurume University
Development of "nano-ball" for tumor suppression by specific		Hitoshi Sasaki





using iPS cell-based technologies

delivery of nucleic acid medicines to cancer cells in the lung

Development of small molecule compounds for cystic fibrosis

Nagasaki University

Yuki Yamamoto

Kyoto University